
Alessandro Santin, MD, discusses the investigation of sacituzumab govitecan in patients with recurrent endometrial carcinoma overexpressing TROP2.

Your AI-Trained Oncology Knowledge Connection!


Alessandro Santin, MD, discusses the investigation of sacituzumab govitecan in patients with recurrent endometrial carcinoma overexpressing TROP2.

Alessandro Santin, MD, discusses the clinical activity of sacituzumab govitecan-hziy in patients with recurrent endometrial cancer who overexpress Trop-2.

Alessandro D. Santin, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses the impact of trastuzumab (Herceptin) in patients with uterine serous carcinoma.

Alessandro D. Santin, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses the rationale for trastuzumab (Herceptin) in the treatment of patients with uterine serous carcinoma.

Published: March 30th 2018 | Updated:

Published: April 24th 2018 | Updated: